<?xml version="1.0" encoding="UTF-8"?>
<ref id="bjh15394-bib-0016">
 <mixed-citation publication-type="journal" id="bjh15394-cit-0016">
  <string-name>
   <surname>Gupta</surname>, 
   <given-names>N.</given-names>
  </string-name>, 
  <string-name>
   <surname>Zhao</surname>, 
   <given-names>Y.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hui</surname>, 
   <given-names>A.M.</given-names>
  </string-name>, 
  <string-name>
   <surname>Esseltine</surname>, 
   <given-names>D.L.</given-names>
  </string-name> &amp; 
  <string-name>
   <surname>Venkatakrishnan</surname>, 
   <given-names>K.</given-names>
  </string-name> (
  <year>2015a</year>) 
  <article-title>Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis</article-title>. 
  <source xml:lang="en">British Journal of Clinical Pharmacology</source>, 
  <volume>79</volume>, 
  <fpage>789</fpage>–
  <lpage>800</lpage>.
  <pub-id pub-id-type="pmid">25377318</pub-id>
 </mixed-citation>
</ref>
